Abstract
The serological tests represent a significant advance in screening at-risk patients for celiac disease and probably should supplant other nonspecific methods for screening, such as 72-hr fecal fat, the d-xylose test, serum carotene, or small-bowel x-ray. The latter tests lack sensitivity, specificity, or simplicity. The published results suggest that the EMA IgA IFA is currently the screening tool of choice. The demonstration of the characteristic histological abnormalities of the intestinal abnormality and clinical improvement on a gluten-free diet is the gold standard for the diagnosis of celiac disease. Whether serological testing can substitute for intestinal biopsy in the diagnosis of celiac disease will depend on the experience obtained from more widespread application of these tests. The greater availability and more frequent use of these tests should increase the detection of a readily treatable condition, the diagnosis of which is often greatly delayed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
More From: Clinical Immunology Newsletter
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.